AR107434A1 - Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano - Google Patents
Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decanoInfo
- Publication number
- AR107434A1 AR107434A1 ARP170100091A ARP170100091A AR107434A1 AR 107434 A1 AR107434 A1 AR 107434A1 AR P170100091 A ARP170100091 A AR P170100091A AR P170100091 A ARP170100091 A AR P170100091A AR 107434 A1 AR107434 A1 AR 107434A1
- Authority
- AR
- Argentina
- Prior art keywords
- unsubstituted
- membered
- unsaturated
- saturated
- unit
- Prior art date
Links
- 229920006395 saturated elastomer Polymers 0.000 abstract 29
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 23
- 125000001424 substituent group Chemical group 0.000 abstract 12
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 abstract 6
- 125000006707 (C3-C12) heterocycloalkyl group Chemical group 0.000 abstract 5
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 5
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16151012 | 2016-01-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107434A1 true AR107434A1 (es) | 2018-05-02 |
Family
ID=55129633
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100091A AR107434A1 (es) | 2016-01-13 | 2017-01-13 | Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano |
| ARP220100097A AR124672A2 (es) | 2016-01-13 | 2022-01-18 | Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100097A AR124672A2 (es) | 2016-01-13 | 2022-01-18 | Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US20170197970A1 (enExample) |
| EP (2) | EP3722284B1 (enExample) |
| JP (2) | JP6893516B2 (enExample) |
| KR (2) | KR102768715B1 (enExample) |
| CN (2) | CN108699006B (enExample) |
| AR (2) | AR107434A1 (enExample) |
| AU (1) | AU2017206908B2 (enExample) |
| BR (1) | BR112018014305B1 (enExample) |
| CA (1) | CA3011176C (enExample) |
| CL (1) | CL2018001911A1 (enExample) |
| CO (1) | CO2018008447A2 (enExample) |
| CY (1) | CY1122923T1 (enExample) |
| DK (2) | DK3722284T3 (enExample) |
| EA (2) | EA202190281A1 (enExample) |
| EC (1) | ECSP18060834A (enExample) |
| ES (2) | ES2807549T3 (enExample) |
| FI (1) | FI3722284T3 (enExample) |
| HR (2) | HRP20250176T1 (enExample) |
| HU (2) | HUE049771T2 (enExample) |
| IL (2) | IL260496B (enExample) |
| LT (2) | LT3402781T (enExample) |
| MX (1) | MX378607B (enExample) |
| PE (1) | PE20221732A1 (enExample) |
| PL (2) | PL3402781T3 (enExample) |
| PT (2) | PT3402781T (enExample) |
| RS (2) | RS60307B1 (enExample) |
| SI (2) | SI3722284T1 (enExample) |
| TW (1) | TWI635082B (enExample) |
| WO (1) | WO2017121647A1 (enExample) |
| ZA (1) | ZA201805356B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR107360A1 (es) | 2016-01-13 | 2018-04-25 | Gruenenthal Gmbh | Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano |
| JP6917379B2 (ja) | 2016-01-13 | 2021-08-11 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | ８−アミノ−２−オキソ−１，３−ジアザ−スピロ−［４．５］−デカン誘導体 |
| HRP20250176T1 (hr) * | 2016-01-13 | 2025-04-11 | Grünenthal GmbH | Derivati 3-((hetero-)aril)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana |
| RS60224B1 (sr) | 2016-01-13 | 2020-06-30 | Gruenenthal Gmbh | Derivati 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana |
| US10961242B2 (en) * | 2017-05-17 | 2021-03-30 | Legochem Biosciences, Inc. | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same |
| EP3908581A1 (en) | 2019-01-11 | 2021-11-17 | Grünenthal GmbH | Substituted pyrrolidine amides iii |
| CN110862395B (zh) * | 2019-11-13 | 2020-09-29 | 株洲千金药业股份有限公司 | 一种制备他达拉非重要杂质的原料化合物的制备方法 |
| US20240400537A1 (en) | 2023-04-25 | 2024-12-05 | Gruenenthal Gmbh | Cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2734265B1 (fr) | 1995-05-17 | 1997-06-13 | Adir | Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant |
| KR100855204B1 (ko) | 2001-04-18 | 2008-09-01 | 유로-셀티크 소시에떼 아노뉨 | 노시셉틴 유사체 |
| DE10130020A1 (de) | 2001-06-25 | 2003-12-04 | Gruenenthal Gmbh | Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate |
| DE10210195B4 (de) | 2002-03-07 | 2005-12-15 | Schwarz Pharma Ag | Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz |
| EA009789B1 (ru) | 2002-07-05 | 2008-04-28 | Таргасепт, Инк. | N-арилдиазаспирациклические соединения и способы их получения и применения |
| DE10252667A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| NZ544282A (en) | 2003-05-23 | 2009-07-31 | Zealand Pharma As | Triaza-spiro compounds as nociceptin analogues and uses thereof |
| JO2676B1 (en) | 2004-04-06 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines |
| DE102005044813A1 (de) | 2005-05-19 | 2007-10-04 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| DE102005023784A1 (de) | 2005-05-19 | 2006-11-30 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| DE102005030051A1 (de) | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| DE102006019597A1 (de) | 2006-04-27 | 2007-10-31 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| RU2439062C2 (ru) | 2006-10-19 | 2012-01-10 | Ф.Хоффманн-Ля Рош Аг | Производные имидазолона и имидазолидинона как 11в-hsd1 ингибиторы при диабете |
| EP2121624A1 (en) * | 2007-02-01 | 2009-11-25 | Glaxo Group Limited | Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders |
| CA2683598C (en) | 2007-04-09 | 2015-11-17 | Janssen Pharmaceutica Nv | 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression |
| ES2694103T3 (es) | 2008-03-27 | 2018-12-18 | Grünenthal GmbH | Derivados de 4-aminociclohexano sustituidos |
| TW201038572A (en) | 2009-03-25 | 2010-11-01 | Gruenenthal Gmbh | Substituted spiro-amide compounds |
| WO2010151815A2 (en) | 2009-06-25 | 2010-12-29 | Abbott Laboratories | 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof |
| TWI582092B (zh) | 2010-07-28 | 2017-05-11 | 歌林達股份有限公司 | 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物 |
| MA40170A (fr) | 2014-06-13 | 2017-04-19 | Purdue Pharma Lp | Dérivés hétérocycliques de morphinan et leur utilisation |
| AR107360A1 (es) | 2016-01-13 | 2018-04-25 | Gruenenthal Gmbh | Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano |
| RS60224B1 (sr) | 2016-01-13 | 2020-06-30 | Gruenenthal Gmbh | Derivati 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana |
| HRP20250176T1 (hr) | 2016-01-13 | 2025-04-11 | Grünenthal GmbH | Derivati 3-((hetero-)aril)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana |
| JP6917379B2 (ja) | 2016-01-13 | 2021-08-11 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | ８−アミノ−２−オキソ−１，３−ジアザ−スピロ−［４．５］−デカン誘導体 |
| PL3402783T3 (pl) | 2016-01-13 | 2020-08-24 | Grünenthal GmbH | Pochodne 3-(karboksyetylo)-8-amino-2-okso-1,3-diazaspiro-[4.5]-dekanu |
| UY37073A (es) | 2016-01-13 | 2017-07-31 | Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen |
| AU2017207862B2 (en) | 2016-01-13 | 2020-12-17 | Novo Nordisk A/S | EGF(A) analogues with fatty acid substituents |
-
2017
- 2017-01-13 HR HRP20250176TT patent/HRP20250176T1/hr unknown
- 2017-01-13 US US15/405,485 patent/US20170197970A1/en not_active Abandoned
- 2017-01-13 AU AU2017206908A patent/AU2017206908B2/en active Active
- 2017-01-13 RS RS20200593A patent/RS60307B1/sr unknown
- 2017-01-13 LT LTEP17700389.4T patent/LT3402781T/lt unknown
- 2017-01-13 DK DK20155715.4T patent/DK3722284T3/da active
- 2017-01-13 EA EA202190281A patent/EA202190281A1/ru unknown
- 2017-01-13 CA CA3011176A patent/CA3011176C/en active Active
- 2017-01-13 EA EA201891611A patent/EA037598B1/ru unknown
- 2017-01-13 HU HUE17700389A patent/HUE049771T2/hu unknown
- 2017-01-13 EP EP20155715.4A patent/EP3722284B1/en active Active
- 2017-01-13 PT PT177003894T patent/PT3402781T/pt unknown
- 2017-01-13 LT LTEP20155715.4T patent/LT3722284T/lt unknown
- 2017-01-13 ES ES17700389T patent/ES2807549T3/es active Active
- 2017-01-13 TW TW106101124A patent/TWI635082B/zh active
- 2017-01-13 KR KR1020247014797A patent/KR102768715B1/ko active Active
- 2017-01-13 HU HUE20155715A patent/HUE070444T2/hu unknown
- 2017-01-13 JP JP2018536436A patent/JP6893516B2/ja active Active
- 2017-01-13 EP EP17700389.4A patent/EP3402781B1/en active Active
- 2017-01-13 FI FIEP20155715.4T patent/FI3722284T3/fi active
- 2017-01-13 WO PCT/EP2017/025005 patent/WO2017121647A1/en not_active Ceased
- 2017-01-13 AR ARP170100091A patent/AR107434A1/es active IP Right Grant
- 2017-01-13 SI SI201731589T patent/SI3722284T1/sl unknown
- 2017-01-13 PL PL17700389T patent/PL3402781T3/pl unknown
- 2017-01-13 SI SI201730263T patent/SI3402781T1/sl unknown
- 2017-01-13 RS RS20250212A patent/RS66559B1/sr unknown
- 2017-01-13 PL PL20155715.4T patent/PL3722284T3/pl unknown
- 2017-01-13 KR KR1020187021552A patent/KR102719137B1/ko active Active
- 2017-01-13 ES ES20155715T patent/ES3014458T3/es active Active
- 2017-01-13 DK DK17700389.4T patent/DK3402781T5/da active
- 2017-01-13 CN CN201780006506.5A patent/CN108699006B/zh active Active
- 2017-01-13 BR BR112018014305-7A patent/BR112018014305B1/pt active IP Right Grant
- 2017-01-13 PE PE2022001338A patent/PE20221732A1/es unknown
- 2017-01-13 HR HRP20200782TT patent/HRP20200782T1/hr unknown
- 2017-01-13 PT PT201557154T patent/PT3722284T/pt unknown
- 2017-01-13 MX MX2018008643A patent/MX378607B/es unknown
- 2017-01-13 CN CN202111487304.1A patent/CN114149413A/zh active Pending
-
2018
- 2018-03-16 US US15/923,948 patent/US20180201616A1/en not_active Abandoned
- 2018-07-09 IL IL260496A patent/IL260496B/en unknown
- 2018-07-13 CL CL2018001911A patent/CL2018001911A1/es unknown
- 2018-08-10 ZA ZA2018/05356A patent/ZA201805356B/en unknown
- 2018-08-13 CO CONC2018/0008447A patent/CO2018008447A2/es unknown
- 2018-08-13 EC ECSENADI201860834A patent/ECSP18060834A/es unknown
- 2018-12-03 US US16/207,854 patent/US20190106429A1/en not_active Abandoned
-
2019
- 2019-06-24 US US16/450,331 patent/US10807988B2/en active Active
-
2020
- 2020-05-21 CY CY20201100466T patent/CY1122923T1/el unknown
- 2020-09-02 US US17/010,089 patent/US20210032256A1/en not_active Abandoned
-
2021
- 2021-03-01 US US17/188,860 patent/US20210188860A1/en not_active Abandoned
- 2021-03-02 JP JP2021032291A patent/JP7148660B2/ja active Active
- 2021-08-04 IL IL285355A patent/IL285355B2/en unknown
-
2022
- 2022-01-18 AR ARP220100097A patent/AR124672A2/es not_active Application Discontinuation
- 2022-11-14 US US17/986,207 patent/US20230303573A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124672A2 (es) | Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
| AR107360A1 (es) | Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
| AR107359A1 (es) | Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
| AR107361A1 (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
| AR107358A1 (es) | Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
| AR094684A1 (es) | Triterpenoides de c-19 modificados, con actividad inhibidora de la maduración del vih | |
| AR095326A1 (es) | Heterociclos tricíclicos como inhibidores de la proteína bet | |
| AR105104A1 (es) | Derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| AR113888A1 (es) | Derivados de indol macrocíclicos sustituidos | |
| AR106299A1 (es) | Compuestos de piridona y fungicidas agrícolas y hortícolas que contienen dichos compuestos como ingrediente activo | |
| AR107488A1 (es) | Compuestos de benzopirazol y análogos de éstos | |
| AR111776A1 (es) | Heteroarilos inhibidores de las proteínas ras mutantes de g12c | |
| AR109974A2 (es) | Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes | |
| AR110988A1 (es) | Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados | |
| AR110227A2 (es) | Derivados de pirazol con acción sobre fgf | |
| AR100879A1 (es) | Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas | |
| AR105075A1 (es) | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales | |
| BR112017007708B8 (pt) | Composto macrocíclico e composição farmacêutica | |
| AR095040A1 (es) | Antagonistas de h3 que contienen un núcleo estructural de fenoxipiperidina | |
| AR091310A1 (es) | Antibioticos de peptidos lineales | |
| AR100706A1 (es) | Derivados de naftiridinadiona | |
| AR102222A1 (es) | Compuestos de indolinona, composiciones farmacéuticas que los comprende y usos de los mismos | |
| AR097795A1 (es) | Derivados de n-arilmetilo sulfonamida como moduladores negativos de nr2a | |
| AR093796A1 (es) | Derivados del alcohol 1-fenil-2-piridinil alquilico como inhibidores de la fosfodiesterasa | |
| AR105360A1 (es) | Hidrazidas de ácido carboxílico heteroarilo sustituidas o sus sales y su uso para aumentar la tolerancia al estrés en plantas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |